Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfectious inflammation. In addition to safety issues, the drug itself may have variable efficacy associated with product aliquoting, handling, and distribution.
To conduct surveillance cultures, evaluate endotoxin levels, and assess protein concentrations ...
JAMA Ophthalmol. Published online September 18, 2014. doi:10.1001/jamaophthalmol.2014.3591